Morphoproteomic expression of H-ras (p21ras) correlates with serum monoclonal immunoglobulin reduction in multiple myeloma patients following pamidronate treatment

Annals of Clinical and Laboratory Science

Volumn 37, Issue 1, 2007, Pages 34-38

  Zhang, Ping L ^a,b   Quiery Jr , Albert T ^a   Blasick, Thomas M ^b   Brown, Robert E ^a  

^a GEISINGER MEDICAL CENTER   (United States)

^b WEIS CENTER FOR RESEARCH   (United States)

Author keywords

Bisphosphonates; H ras; Multiple myeloma; Pamidronate; Serum monoclonal Ig; Zoledronate

Indexed keywords

BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; GERANYLTRANSFERASE; H RAS PROTEIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; N RAS PROTEIN; PAMIDRONIC ACID; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN P21; RAS PROTEIN; UNCLASSIFIED DRUG; ZOLEDRONIC ACID; FARNESYL TRANS TRANSFERASE; GERANYLGERANYLTRANSFERASE TYPE I; GERANYLGERANYLTRANSFERASE TYPE-I; HRAS PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; TRANSFERASE;

ARTICLE; BONE MARROW BIOPSY; CANCER PATIENT; CELL PROLIFERATION; CLINICAL ARTICLE; CONTINUOUS INFUSION; DRUG SUBSTITUTION; ENZYME SUBUNIT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYELOMA CELL; OSTEOCLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; TREATMENT OUTCOME; BLOOD; COMPARATIVE STUDY; METABOLISM; UNITED STATES;

ALKYL AND ARYL TRANSFERASES; BIOLOGICAL MARKERS; CELL PROLIFERATION; DIPHOSPHONATES; FARNESYLTRANSTRANSFERASE; HUMANS; IMIDAZOLES; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOHISTOCHEMISTRY; MULTIPLE MYELOMA; PENNSYLVANIA; PROTO-ONCOGENE PROTEINS P21(RAS);

EID: 33847672727     PISSN: 00917370     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Bergstrom JD, Bostedor RG, Masarachia PJ, Rezka AA, Rodan G. Alendronate is a specific, nanomolar inhibitor of farnesyl disphosphonate synthase. Arch Biochem Biophys 2000;373:231-241.
2. Cox AD. Farnesyltransferase inhibitors-potential role in the treatment of cancer. Drugs 2001;61:723-732.
3. Whyte DB, Kirschmeier P, Hockenberry TH, Numez-Oliva I, James L, Catino JJ, Bishop WR, Pai J. K- and N-ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem 1997;272: 14459-14464.
4. Sausville EA, Elsayed Y, Monga M, Kim G. Signal transduction-directed cancer treatment. Ann Rev Pharmacol Toxicol 2003;43:199-231.
5. Berenson J, Hillner BE, Kyle RA, Anderson K, Lipton A, Yee GC, Biemann JS. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol 2002;17: 3719-3736.
6. Riedel DA, Potter LM. The epidemiology of multiple myeloma. Hematol Oncol Clin North Am 1992;6:225-247.
7. Jantunen E. Bisphosphonate therapy in multiple myeloma: past, present, future. Eu J Hematol 2002;69:257-264.
8. Rosen L, Harland SJ, Oosterlinck W. Broad clinical activity of zoledronate acid in osteolytic to osteoblastic bone lesions in patients with a broad range of solid tumors. Am J Clin Oncol 2002;25:S19-S24.
9. Kondo H, Mori A. Anti-tumor activity of pamidronate in human multiple myeloma. Leuk Lymphoma 2002; 43:919-921.
10. Dhodapkar MV, Singh J, Mehta J, Passas A, Desikan FK. Anti-myeloma activity of pamidronate in in vivo. Br J Haematol 1998;103:530-532.
11. Corso A, Astori C, Orlandi E, Zappasodi P, Arcaini L, Bernasconi C. Transient response of myeloma clone to pamidronate therapy. Haematologica 1999;84:759-760.
12. Lipton A. Bisphosphonates and metastatic breast carcinoma. Cancer 2003;97:848-853.
13. Coleman RE. Current and future status of adjuvant therapy for breast cancer. Cancer 2003;97:880-886.
14. Zhang PL, Lun M, Siegelmann-Danieli N, Blasick TM, Brown RE. Pamidronate resistance and associated low ras levels in breast cancer cells: a role for combinatorial therapy. Ann Clin Lab Sci 2004;34:263-270.